Insulin glargine in type 2 diabetes in everyday clinical practice: 7years experience

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL.2, 2008, Pages 24-34

  Schreiber, S A ^a  

^a Diabetes Zentrum Schreiber   (Germany)

Author keywords

Clinical practice; Hypoglycaemia; Insulin glargine; Long acting insulin; Titration

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

BEHAVIOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TITRIMETRY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT EDUCATION AS TOPIC; POWER (PSYCHOLOGY); RANDOMIZED CONTROLLED TRIALS AS TOPIC; TITRIMETRY;

EID: 63449088661     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00842.x     Document Type: Review

References (34)

1. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007; 22: 453-458.
2. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350-358.
3. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 810-816.
4. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005; 28: 995-1000.
5. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
6. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
7. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
8. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
9. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619.
10. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
11. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.
12. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
13. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
14. Tanenberg R, Stewart J, Zisman A. Glycemia optimization treatment (GOT): glycaemic control and rate of severe hypoglycemia for 5 different dosing algorithms of insulin glargine in patients with type 2 diabetes mellitus (Abstract 986). Diabetologia 2006; 49 (Suppl. 1): 601-602.
15. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
16. Cryer P, Childs B. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum 2002; 15: 20-27.
17. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
18. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
20. Snoek FJ, Dain M, Polonsky W. Perceptions of seriousness and management of diabetes. Findings from the SHARED study (Survey comparing Healthcare professionals and patients to Assess REal perceptions of Diabetes issues) (Abstract 699). Diabet Med 2006; 23 (Suppl. 4): 259.
21. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
22. Davies M, Evans R, Storms F, Gomis R, Khunti K. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 2007; 9: 706-713.
23. Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006; 22: 335-341.
24. Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006; 114: 41-42.
25. Yki-Jarvinen H, Juurinen L, Alvarsson M et al. INITIATE (INITiate Insulin by Aggressive Titration and Education). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
26. Levin P. The cost-effectiveness of insulin glargine versus NPH insulin in type 2 diabetes: a focus on health economics. Diabetes Obes Metab 2008; 10 (Suppl. 2): 66-77.
27. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12, 216 patients. Diabetes Obes Metab 2007; 9: 31-38.
28. Schreiber SA, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008; 10: 121-127.
29. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61(12): 2009-2018.
30. Ruhnau K-J, Schneider K, Schweitzer MA. Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 2 diabetes in daily practice (Abstract 2152-PO). Diabetes 2005; 54 (Suppl. 1): A518.
31. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005; 21: 565-570.
32. Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 23 (Suppl. 1): 33-39.
33. ADA. Standards of Medical Care in Diabetes - 2006. Diabetes Care 2006; 29 (Suppl. 1): S4-S42.
34. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005.